With expansion a prime focus for businesses worldwide, many are looking towards rapidly establishing new regions of growth, particularly in Asia, Pacifi c Rim countries.
ASIA
Yangon General Hospital Installs Cancer Treatment Systems
The new high-dose-rate (HDR) brachytherapy system delivers radiotherapy directly to a tumour site from inside the body.
The 1500 bed Yangon General Hospital has medical, surgical, trauma and orthopaedic wards, plus 24 specialised departments for inpatient care and runs an ER for general medicine, surgery and trauma. With 300 doctors and over 400 nurses. It is also the Tertiary Care Teaching Hospital of University of Medicine 1, the country’s premier medical school, as well as the Yangon Institute of Nursing and the University of Paramedical Science.
by Heather Hobbs To appear in our next issue, send your Business and Financial News stories to
heather@intlabmate.com
This section of International Labmate will especially look at the success of both Asian and European companies with established premises or business partnerships, highlighting the opportunities that exist while realising potential for other companies to move into export markets.
Nanostart AG: Market Entry in China
The Frankfurt-based investment company Nanostart AG has entered into a joint venture through its Asian subsidiary Nanostart Asia Pte Ltd, with the Chinese asset manager Westbridge Asset Management Ltd. The venture capitalist has a 50% stake in the newly founded asset manager Nanostart Westbridge Company Ltd, based in Hong Kong.
Over the coming months, the asset manager will be launching funds in China in association with the Chinese government. The fi rst funds are already expected to have a cumulative volume in the range of triple digit millions of euros.
Professor Dr Pe Thet Khin, Myanmar’s Minister of Health, addresses guests at the Opening Ceremony at Yangon General Hospital
Yangon General Hospital has become the fi rst clinical site in Myanmar to install technology from Varian Medical Systems for treating cancer with radiotherapy. In February the hospital unveiled its new medical linear accelerator plus technology for high-dose-rate brachytherapy at a Grand Opening that was attended by Professor Dr Pe Thet Khin, Myanmar’s Minister of Health.
“We chose Varian technology because it will enable us to upgrade the quality of treatment that we can offer cancer patients in Myanmar,” said Professor Soe Oo-Mg, Head of the Radiation Oncology Department at Yangon General.
The hospital’s new medical linear accelerator system is outfi tted for intensity-modulated radiotherapy (IMRT), which enables clinicians to shape the treatment beam to match the shape and size of the targeted tumour. “This machine is fully capable of delivering high-quality treatments for many types of cancer, and upgradable in the future for addressing a wider range of cases that are more diffi cult to treat,” said Kevin Lo, Director of Asia Pacifi c marketing for Varian.
Professor Dr Pe Thet Khin, Myanmar’s Minister of Health, (3rd from left) talks with guests about the new linear accelerator from Varian Medical Systems recently installed at the Yangon General Hospital.
According to the World Health Organisation, over 60,000 new cancer cases are estimated to occur each year in Myanmar, with breast cancer the most common among women, and lung cancer the most common among men.
29339pr@reply-direct.com
A signifi cant amount of the fund volume is to be invested in Germany, the rest regionally in China. The funds will be invested in high-tech companies with a focus on nanotechnology, but may also take a share in promising technology companies with no connection to nanotechnology. The aim is to offer the German holdings of the funds a bridge to Chinese partner groups with access to the Chinese market.
“Our new asset manager Nanostart Westbridge is not only the result of almost two years of intensive work in China, but it also marks the most signifi cant strategic event in the history of Nanostart AG. For Nanostart AG, the joint launching of funds with the Chinese government represents a successful market entry into the second largest national economy in the world and has the potential to raise us to a leading asset manager over the coming years,” explained Marco Beckmann, Chairman of Nanostart AG. “We are delighted to have found an internationally experienced partner in Nanostart AG, whose global network offers outstanding opportunities to lead the newly developed German-Chinese venture capital funds to great success,” adds Dr KK Chan, Managing Director of Westbridge Asset Management Ltd. “With our funds, we are a fi rst mover in an emerging class of internationally oriented venture capital funds and we are enabling the accelerated growth of emergent technology companies in two of the most important markets in the world.”
29338pr@reply-direct.com India and UK Collaborate on Animal Health
Sir Mark Walport, the UK Government Chief Scientifi c Adviser, has announced major funding to protect livestock, during a recent visit to India. The research projects aim to tackle major livestock diseases which threaten food security in the UK and globally.
£6.5 million has been awarded by the UK’s Biotechnology and Biological Sciences Research Council (BBSRC), with matched funding from India’s Department of Biotechnology (DBT), for collaborative research projects between universities and research institutes in both countries. It is the fi rst international call on animal health for DBT and covers many important livestock species.
Science Minister David Willetts said: “In the face of a rapidly growing global population, it is vital that we work together to fi nd innovative solutions to animal diseases and global food security. This signifi cant £13 million investment is ensuring this important work can take place and supports the Government’s wider Agri-Tech strategy. This is helping UK businesses, including farmers, make the best use of new technologies and techniques to meet the needs of
consumers and food producers worldwide, as well as contributing to economic growth.”
Professor Jackie Hunter, BBSRC Chief Executive said: “Livestock health is a huge global problem, impacting on the economy and food security. These projects will enable collaboration and shared knowledge in a bid to create novel control measures and technologies to combat infectious diseases that devastate farms in the UK and India.”
The projects include: research towards TB control in cattle; understanding the different responses to avian Infl uenza viruses; studying tick-borne disease; creating biosensors for infectious reproductive diseases of cattle; assisting a global alliance against the goat plague ‘Peste des Petits Ruminants’; fi nding an effective vaccination programme for the eradication of foot-and-mouth disease in India, and understanding why some animals have disease immunity.
29349pr@reply-direct.com South Korean Authority
Approves Inhaler Use Vectura Group plc confi rms that its partner Sandoz, has received South Korean marketing authorisation for AirFluSal® Forspiro® an innovative inhaler for patients with asthma and chronic obstructive pulmonary disease (COPD), making it the fi rst approval in Asia.
The product was fi rst approved in Denmark on December 18th, 2013, with subsequent approvals in Germany, Belgium, Sweden, Norway, Hungary, Romania and Bulgaria and the product has now been launched in Denmark and Germany. The new product offers the proven combination of salmeterol (a long-acting inhaled β2-agonist) and fl uticasone (an inhaled corticosteroid) in an inhalation device which has visual control features which help reassure the patient about dosing.
The inhaler was awarded the Red Dot Product Design award in 2011, an internationally recognised quality seal awarded by the Design Zentrum Nordrhein Westfalen in Essen, Germany. It is displayed in design museums in Essen and Singapore.
Does your company sell or wish to sell laboratory products and services to the economies of Asia? Are you looking for local distributors and agents to represent you?
If so, why not advertise your products in our market-leading journal International Labmate. Email:
info@intlabmate.com
South Korea has approved the 50µg-250µg and 50µg- 500µg dosage forms for the continuous treatment of patients above 12 years of age with persistent asthma or for symptomatic treatment of COPD.
29340pr@reply-direct.com
Business
Opportunities
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84
